Cassava Sciences (NASDAQ:SAVA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.11, Zacks reports.
Cassava Sciences Price Performance
Cassava Sciences stock traded up $0.06 during mid-day trading on Thursday, hitting $2.82. 1,572,296 shares of the company's stock traded hands, compared to its average volume of 2,844,869. The firm has a 50 day simple moving average of $2.55 and a two-hundred day simple moving average of $15.03. Cassava Sciences has a fifty-two week low of $2.23 and a fifty-two week high of $42.20. The stock has a market cap of $135.67 million, a price-to-earnings ratio of -2.04 and a beta of -1.24.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "neutral" rating on shares of Cassava Sciences in a research note on Tuesday.
View Our Latest Analysis on Cassava Sciences
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Read More
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
